EP3952840A1 - Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders - Google Patents
Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disordersInfo
- Publication number
- EP3952840A1 EP3952840A1 EP19924315.5A EP19924315A EP3952840A1 EP 3952840 A1 EP3952840 A1 EP 3952840A1 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A1 EP3952840 A1 EP 3952840A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- memantine
- azelastine
- pharmaceutical composition
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to the field of practical medicine, namely, to the combined use of pharmaceutical compositions exhibiting a neurotropic action, alleviating manifestations of mental, behavioral, cognitive disorders in cases of organic damage of various origin to the central nervous system.
- AD Alzheimer's disease
- Dementia is the loss of cognitive functioning— thinking, remembering, and reasoning— and behavioral abilities to such an extent that it interferes with a person’s daily life and activities.
- memory loss is mild, but with late-stage AD, individuals lose the ability to carry on a conversation and respond to their environment. If untreated, AD ultimately leads to death.
- the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.
- LTP long-term potentiation
- LTP is mediated by the neurotransmitter glutamate via the NMDA receptor.
- the NMDA receptors can be found diffusely throughout the brain. However, they densely populate the dendrites of pyramidal cells in the hippocampus and cortex (areas known to be involved in cognition, learning, and memory). In addition to the relationship between LTP and learning, elevated glutamate levels are associated with excitotoxicity. Chronic low-dose administration of NMDA receptor agonists has been shown to induce apoptosis, while high doses induce necrosis. The activation of glutamate receptors has also been found to induce the release of glutamate. Thus, a large build-up of glutamate can occur and induce a massive accumulation of Ca2+, leading to apoptosis.
- amyloid-beta (AB) plaques increase a neuron’s vulnerability to excitotoxicity.
- AB plaques a pathological feature of AD, were found to induce depolarization of astrocytes, extracellular accumulation of glutamate, and intracellular deposition of Ca2+. Therefore, the glutamate-induced excitotoxicity pathway made an excellent target for the therapy of AD.
- NMDA receptors act as a calcium [II] ion (Ca2+) channel that activates when bound by glycine, glutamate, and/or NMDA.
- Ca2+ calcium [II] ion
- Mg2+ magnesium [II] ion
- NMDA receptor antagonists are looked to as possible neuroprotective agents and potential therapies for neurodegenerative disease.
- NMDA antagonists are competitive antagonists and are not well tolerated by patients due to side effects, which can include hallucinations and schizophrenia-type symptoms.
- the side effects likely result from the competitive antagonists blocking physiological functions of the NMDA receptor. Its role in cognition, memory, and learning make it necessary that any drug using the NMDA receptor as a target of action must preserve physiologic function to be therapeutically useful.
- Memantine acts on activated NMDA receptors by binding to a site located in the channel of the receptor.
- Memantine is a fast-binding antagonist which binds to the channel in a pseudo- first order manner. However, it also dissociates from the receptor quickly and in a concentration independent manner. This allows the dose to affect the binding of memantine without affecting its removal from the site of action and allowing for increased potency with minimal side effects. In comparison with other antagonists, memantine has a much faster course of action and thus has less effect on physiologic mechanisms. For this reason, memantine offers a lot of promise in the therapy of neurodegenerative disease because it will preserve physiological function. In addition, the uncompetitive nature of memantine’s mechanism of action makes its antagonistic activity more potent in areas with massive activation of NMDA receptors.
- Memantine s mechanism of action is also voltage-dependent, which leads to the removal of the memantine blockage by depolarization of the membrane. All of these characteristics make memantine a strong candidate for treating pathology induced by excito toxicity. In several studies, memantine was found to prevent neuronal death induced via excitotoxic mechanisms.
- AD support the evidence that activated immune and inflammatory processes is a part of the disease. Also, a strong benefit of long-term use of NSAIDs was shown in epidemiological studies. So, it is generally accepted that AD is partially an inflammatory disease and that inhibiting inflammation is an option of treating AD.
- Inflammation clearly occurs in pathologically vulnerable regions of the AD brain, and it does so with the full complexity of local peripheral inflammatory responses.
- degenerating tissue and the deposition of highly insoluble abnormal materials are classical stimulants of inflammation.
- damaged neurons and neurites and highly insoluble amyloid b peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation. Because these stimuli are discrete, micro-localized, and present from early preclinical to terminal stages of AD, local upregulation of complement, cytokines, acute phase reactants, and other inflammatory mediators is also discrete, micro-localized, and chronic.
- Azelastine is classified pharmacologically as a second generation antihistamine and is a relatively selective, non- sedating, competitive antagonist at HI receptors. More uniquely, its inhibition of inflammatory mediators, in addition to antihistaminic and mast cell stabilizing effects, places it among the new generation of dual-acting anti-inflammatory drugs. In addition to azelastine’ s high affinity for HI receptors, its ability to modify several other mediators of inflammation and allergy contributes to its mechanism of action. In vitro and in vivo studies, as well as clinical trials support the dual effects of direct inhibition and stabilization of inflammatory cells.
- azelastine s affinity for HI receptors is estimated to be several times greater than that of chlorpheniramine, a first- generation HI antagonist.
- Azelastine has only weak affinity for H2 receptors. Release of histamine from mast cells is also inhibited possibly by reversible inhibition of voltage-dependent L-type calcium channels. Inhibition of mast cell degranulation may also decrease the release of other inflammatory mediators, including leukotrienes and interleukin- 1b, among others.
- Azelastine also directly antagonizes other mediators of inflammation, such as tumor necrosis factor-a, leukotrienes, endothelin-1, and platelet- activating factor.
- the present invention includes a pharmaceutical composition that comprises two active ingredients and one or more pharmaceutically acceptable excipients.
- This pharmaceutical composition comprises the first active ingredient that is azelastine or a pharmaceutically acceptable salt of azelastine and the second active ingredient that is memantine or a pharmaceutically acceptable salt of memantine.
- the pharmaceutically acceptable salt of azelastine in the pharmaceutical composition is azelastine hydrochloride and the pharmaceutically acceptable salt of memantine in this pharmaceutical composition is memantine hydrochloride.
- azelastine hydrochloride (and/or other salt thereof) in the pharmaceutical composition is provided in an amount of about 1 mg to about 20 mg and/or memantine hydrochloride (and/or other salt thereof) in this pharmaceutical composition is in an amount of about 1 mg to about 30 mg.
- the present invention also includes an oral pharmaceutical dosage form of the pharmaceutical composition that is a solid form or a liquid form.
- the present invention further includes the medical use of the oral pharmaceutical dosage form of the pharmaceutical composition through administration of the dosage form to patients with a neurodegenerative disorder such as Alzheimer's disease, vascular dementia, or Parkinson's disease.
- a neurodegenerative disorder such as Alzheimer's disease, vascular dementia, or Parkinson's disease.
- an oral pharmaceutical dosage form of the pharmaceutical composition containing azelastine hydrochloride (and/or other salt thereof) in an amount of about 6 mg to about 12 mg and/or memantine hydrochloride (and/or other salt thereof) of in an amount of about 2 mg to about 6 mg is administered to patients with late stage Alzheimer's disease
- a pharmaceutical composition with an oral dosage form comprising the active agents, a salt form of azelastine and a salt form of memantine, is suitable for treating patients suffering from mental, behavioral, cognitive disorders.
- Alzheimer's disease dementia, Parkinson's disease, Huntington's disease and combinations of any thereof and other neurodegenerative disorders.
- memantine refers to memantine free base, 1-Amino-
- memantine also includes any pharmaceutically acceptable salt, such as the hydrochloride or HC1 salt.
- the memantine is in the form of its hydrochloride salt, as memantine hydrochloride or memantine HC1. More preferably, in any embodiment of the invention as described herein, reference to the amounts and dosage ranges of memantine in oral dosage forms are to the amounts and dosage ranges of memantine hydrochloride.
- azelastine refers to azelastine free base, or 4-(p-
- azelastine also includes any pharmaceutically acceptable salt, such as the hydrochloride or HC1 salt.
- azelastine is in the form of its hydrochloride salt, as azelastine hydrochloride or azelastine HC1. More preferably, in any embodiment of the invention as described herein, reference to the amounts and dosage ranges of azelastine in the solid oral dosage forms are to the amounts and dosage ranges of azelastine hydrochloride.
- treating means complete cure or incomplete cure, or it means that the symptoms of the underlying disease or associated conditions are at least reduced and/or delayed, and/or that one or more of the underlying cellular, physiological, or biochemical causes or mechanisms causing the symptoms are reduced, delayed and/or eliminated. It is understood that reduced or delayed, as used in this context, means relative to the state of the untreated disease, including the molecular state of the untreated disease, not just the physiological state of the untreated disease.
- the term“effective amount” refers to an amount that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment.
- the therapeutically effective amount will vary depending upon the patient being treated, the weight and age of the patient, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the pharmaceutical compositions may be administered in either single or multiple doses by oral administration. Administration may be via capsule, tablet, or the like.
- the pharmaceutical composition may be formulated for pharmaceutical use using methods known in the art, for example, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems Tenth (by Loyd Allen, 2013) and Handbook of Pharmaceutical Manufacturing Formulations (Volumes 1-6 by Sarfaraz K. Niazi). Accordingly, incorporation of the active compounds and a controlled, or slow release matrix may be implemented.
- Either fluid or solid unit dosage forms can be readily prepared for oral administration.
- conventional ingredients such as dicalcium phosphate, magnesium aluminum silicate, magnesium stearate, calcium sulfate, starch, talc, lactose, acacia, methyl cellulose and functionally similar materials as pharmaceutical excipients or carriers.
- a sustained release formulation may optionally be used. In older or incoherent subjects sustained release formulations may even be preferred.
- Capsules may be formulated by mixing the compound with a pharmaceutical diluent which is inert and inserting this mixture into a hard gelatin capsule having the appropriate size. If soft capsules are desired, a slurry of the compound with an acceptable vegetable, light petroleum or other inert oil can be encapsulated by forming into a gelatin capsule.
- Suspensions, syrups and elixirs may be used for oral administration or fluid unit dosage forms.
- a fluid preparation including oil may be used for oil soluble forms.
- a vegetable oil such as com oil, peanut oil or a flower oil, for example, together with flavoring agents, sweeteners and any preservatives produces an acceptable fluid preparation.
- a surfactant may be added to water to form a syrup for fluid unit dosages.
- Hydro-alcoholic pharmaceutical preparations may be used having an acceptable sweetener, such as sugar, saccharin or a biological sweetener and a flavoring agent in the form of an elixir.
- the solid oral dosage formulation of this disclosure means a form of tablets, caplets, bi-layer tablets, film-coated tablets, pills, capsules, or the like. Tablets in accordance with this disclosure can be prepared by any mixing and tableting techniques that are well known in the pharmaceutical formulation industry. In some examples, the dosage formulation is fabricated by direct compressing the respectively prepared sustained-release portion and the immediate-release portion by punches and dies fitted to a rotary tableting press, ejection or compression molding or granulation followed by compression.
- compositions provided in accordance with the present disclosure are usually administered orally.
- This disclosure therefore provides pharmaceutical compositions that comprise a solid dispersion comprising azelastine and memantine as described herein and one or more pharmaceutically acceptable excipients or carriers including but not limited to, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers, disintegrants, lubricants, binders, glidants, adjuvants, and combinations thereof.
- compositions are prepared in a manner well known in the pharmaceutical arts (see, e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Tenth (by Loyd Allen, 2013) and Handbook of Pharmaceutical Manufacturing Formulations (Volumes 1-6 by Sarfaraz K. Niazi)).
- the pharmaceutical composition may further comprise pharmaceutical excipients such as diluents, binders, fillers, glidants, disintegrants, lubricants, solubilizers, and combinations thereof. Some examples of suitable excipients are described herein.
- the tablet When the pharmaceutical composition is formulated into a tablet, the tablet may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
- the pharmaceutical composition can comprise a) about lmg -
- azelastine HC1 (and/or other salt thereof) and/or b) about lmg to 70mg of memantine HC1 (and/or other salt thereof) or a) about 2mg - 20mg of azelastine HC1 (and/or other salt thereof) and/or b) about 2mg to 30mg of memantine HC1 (and/or other salt thereof) or a) about 8mg - 16mg of azelastine HC1 (and/or other salt thereof) and/or b) about 2mg to 5mg of memantine HC1 (and/or other salt thereof).
- compositions of the invention can comprise a) about 12mg of azelastine HC1 (and/or other salt thereof) and/or b) about 3mg of memantine HC1 (and/or other salt thereof).
- compositions of the invention can comprise azelastine or a pharmaceutically acceptable salt of azelastine present in an amount in the range of about 1 mg to about 50 mg and/or memantine or a pharmaceutically acceptable salt of memantine present in an amount in the range of about 1 mg to about 70 mg.
- the amount of azelastine HC1 (and/or other salt thereof) present in the composition can be equal to, more than, or less than the amount of memantine HC1 (and/or other salt thereof) present in the composition. In embodiments, the amount of azelastine HC1 (and/or other salt thereof) present in the composition can be 2 times as much, or 3 times as much, or 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or 1,000 times as much as the amount of memantine HC1 (and/or other salt thereof) present in the composition, or vice versa. Any one or more of the compositions of the invention can be used with any one or more the methods of the invention disclosed herein, or other methods of using the compositions.
- the amount of the pharmaceutical composition containing azelastine HC1 and memantine HC1 actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.
- compositions, pharmaceutical dosage forms, and tablets containing azelastine HC1 and memantine HC1 as described herein are administered to a patient suffering from a neurodegenerative disorder, such as Alzheimer’s disease, by oral administration once daily, twice daily, once every other day, two times a week, three times a week, four times a week, or five times a week.
- a neurodegenerative disorder such as Alzheimer’s disease
- the pharmaceutical dosage forms and tablets of pharmaceutical compositions containing azelastine HC1 and memantine HC1 as described herein are effective in reversing symptoms in patients with late stage Alzheimer's disease in about 6-24 weeks.
- Example 1 The following Examples are illustrative and should not be interpreted to limit the scope of the claimed subject matter. [0038] Example 1
- Alzheimer's disease He could only speak a few words. He had difficulty in sleeping. His personality was described as illogical or irrational, anxious or irritable, and aggressive or hostile. He was uncooperative most of time. He needed light assistance with walking. He was monitored by an assistant round-the-clock. He was treated with tablets of the pharmaceutical composition containing 14mg of azelastine HC1 and 5mg of memantine HC1. After a month and half, his personality was described as more rational, with much less aggression with no hostility. After 3 months, he could sleep regularly and he no longer needed round-the-clock assistance. He could speak for more than 1 minute. [0044]
- Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990;533(2):315-320.
- Lipton SA Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2): 160-170.
- Severe Impairment Battery domains in patients with moderate-to-severe Alzheimer's disease evaluating the impact of baseline severity,” Alzheimer's Research & Therapy, vol. 5, no. 1, article 12, 2013.
- Alzheimer's dementia a randomised double-blind placebo controlled trial,” PLoS ONE, vol. 7, no. 5, Article ID e35185, 2012.
- Alzheimer's disease in a Japanese population results from a 24-week, double-blind, placebo- controlled, randomized trial,” Dementia and Geriatric Cognitive Disorders, vol. 25, no. 5, pp. 399-407, 2008.
- Epstein AB van Hoven PT, Kaufman A, Carr WW. Management of allergic conjunctivitis: An evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-336.
- Baudouin C Detrimental effect of preservative in eye drops: Implications for the treatment of glaucoma. Acta Ophthalmologica. 2008;86:716-726.
- Ciprandi G Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule- 1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol. 1996;98(6 Pt 1): 1088-1096.
- any of the disclosed compositions can be used with any of the methods disclosed herein or with any other methods.
- Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention. [00121] It is noted in particular that where a range of values is provided in this specification, each value between the upper and lower limits of that range is also specifically disclosed. The upper and lower limits of these smaller ranges may independently be included or excluded in the range as well.
- the singular forms“a,”“an,” and“the” include plural referents unless the context clearly dictates otherwise. It is intended that the specification and examples be considered as exemplary in nature and that variations that do not depart from the essence of the invention fall within the scope of the invention. Further, all of the references cited in this disclosure are each individually incorporated by reference herein in their entireties and as such are intended to provide an efficient way of supplementing the enabling disclosure of this invention as well as provide background detailing the level of ordinary skill in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/027293 WO2020209872A1 (en) | 2019-04-12 | 2019-04-12 | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3952840A1 true EP3952840A1 (en) | 2022-02-16 |
EP3952840A4 EP3952840A4 (en) | 2022-11-23 |
Family
ID=72751206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19924315.5A Pending EP3952840A4 (en) | 2019-04-12 | 2019-04-12 | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3952840A4 (en) |
JP (1) | JP7365426B2 (en) |
CN (1) | CN113939276A (en) |
AU (1) | AU2019445048A1 (en) |
CA (1) | CA3136633A1 (en) |
WO (1) | WO2020209872A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
WO2020222799A1 (en) * | 2019-04-30 | 2020-11-05 | La Pharma Tech Inc. | A method of treating mental, behavioral, cognitive disorders |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2704482T3 (en) * | 2004-11-24 | 2019-03-18 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and its methods of use |
WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
WO2018081508A1 (en) * | 2016-10-28 | 2018-05-03 | Chase Pharmaceutical Corporation | Memantine combinations and use |
JP7198575B2 (en) * | 2017-07-11 | 2023-01-04 | キョーリンリメディオ株式会社 | Orally disintegrating tablet containing memantine hydrochloride |
-
2019
- 2019-04-12 CN CN201980095322.XA patent/CN113939276A/en active Pending
- 2019-04-12 EP EP19924315.5A patent/EP3952840A4/en active Pending
- 2019-04-12 JP JP2021556914A patent/JP7365426B2/en active Active
- 2019-04-12 AU AU2019445048A patent/AU2019445048A1/en not_active Abandoned
- 2019-04-12 WO PCT/US2019/027293 patent/WO2020209872A1/en unknown
- 2019-04-12 CA CA3136633A patent/CA3136633A1/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Also Published As
Publication number | Publication date |
---|---|
CA3136633A1 (en) | 2020-10-15 |
EP3952840A4 (en) | 2022-11-23 |
JP7365426B2 (en) | 2023-10-19 |
JP2022535644A (en) | 2022-08-10 |
AU2019445048A1 (en) | 2021-12-02 |
CN113939276A (en) | 2022-01-14 |
WO2020209872A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10946026B2 (en) | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders | |
JP7365426B2 (en) | Pharmaceutical compositions and methods for treating mental, behavioral, and cognitive disorders | |
US11116773B2 (en) | Method of treating dementia | |
US10639315B1 (en) | Pharmaceutical compositions and methods for treating Alzheimer's disease | |
US11389458B2 (en) | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease | |
EP3962488A1 (en) | A method of treating mental, behavioral, cognitive disorders | |
US10898493B2 (en) | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease | |
US11690849B2 (en) | Method of treating dementia | |
CN114072945A (en) | Novel pharmaceutical compositions and methods for treating psychiatric disorders, behavioral disorders, cognitive disorders | |
KR102547164B1 (en) | Methods of treating neurodegenerative disorders in a particular patient population | |
KR20060117364A (en) | 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
JP2023058666A (en) | Agent for preventing or treating alzheimer-type dementia | |
US10736876B2 (en) | Idalopirdine-based combinatorial therapies of Alzheimer's disease | |
Porsteinsson et al. | Memantine in the treatment of Alzheimer’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221024 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20221018BHEP Ipc: A61K 47/00 20060101ALI20221018BHEP Ipc: A61K 31/495 20060101ALI20221018BHEP Ipc: A61K 31/55 20060101ALI20221018BHEP Ipc: A61K 31/13 20060101ALI20221018BHEP Ipc: A61K 9/48 20060101ALI20221018BHEP Ipc: A61K 9/20 20060101ALI20221018BHEP Ipc: A61K 9/14 20060101ALI20221018BHEP Ipc: A61K 9/10 20060101ALI20221018BHEP Ipc: A61K 9/08 20060101AFI20221018BHEP |